Claim Your Author Page
Although transplantation of c-kit+ cardiac stem cells (CSCs) has been shown to alleviate left ventricular (LV) dysfunction induced by myocardial infarction (MI), the number of exogenous CSCs… (More)
RATIONALE Despite 4 decades of intense effort and substantial financial investment, the cardioprotection field has failed to deliver a single drug that effectively reduces myocardial infarct size in… (More)
The regenerative potential of c-kit(+) cardiac stem cells (CSCs) is severely limited by the poor survival of cells after transplantation in the infarcted heart. We have previously demonstrated that… (More)
We have recently demonstrated that repeated administrations of c-kitPOS cardiac progenitor cells (CPCs) have cumulative beneficial effects in rats with old myocardial infarction (MI), resulting in… (More)
BACKGROUND The authors previously reported that the c-kit-positive (c-kitPOS) cells isolated from slowly adhering (SA) but not from rapidly adhering (RA) fractions of cardiac mesenchymal cells (CMCs)… (More)
Coronary microvascular no-reflow commonly coexists with infarcted cardiomyocyte in reperfused myocardium. Recent studies point to microcirculation as a target, different from infarction size, in ca...
Although cell therapy improves cardiac function after myocardial infarction, highly variable results and limited understanding of the underlying mechanisms preclude its clinical translation. Because… (More)
Persistent pressure overload can cause cardiac hypertrophy and progressive heart failure (HF). The authors developed a pressure-overload HF model of juvenile mice to study the cardiac response to… (More)
Although overexpression of HO-1 in CPCs enhances the efficacy of cell therapy for attenuating LV dysfunction and remodeling after myocardial infarction (MI), its mechanism is unknown. To this end, ...